GlassScriptPhysician profile
Chong H Park
NPI 1346387198
$7,412.82
in general payments reported to CMS, 2019-2025
18 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,727 · 2020: $1,060 · 2021: $1,305 · 2022: $982 · 2023: $603 · 2024: $206 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,547.58 | 2019-2024 | Perclose Prostyle |
| Medtronic, INC. | $1,064.97 | 2021-2025 | Mosaic, Cobalt Dr Mri Surescan, Micra |
| Medtronic Vascular, INC. | $896.01 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $853.85 | 2019-2023 | Jardiance |
| Amgen INC. | $661.83 | 2019-2021 | |
| Amarin Pharma, INC. | $365.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $349.63 | 2019-2021 | |
| Abiomed | $287.83 | 2025 | |
| Novo Nordisk INC | $243.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $236.98 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $217.33 | 2019-2025 | Camzyos |
| Inari Medical, INC. | $195.65 | 2020 | |
| Kestra Medical Technology Services, INC. | $147.66 | 2023 | Assure Wcd |
| Recor Medical INC | $143.07 | 2025 | Paradise Ultrasound Renal Denervation System |
| Astrazeneca Pharmaceuticals LP | $105.83 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $38.09 | 2021-2022 | |
| Pfizer INC. | $33.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chong Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.